BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20250817T075832EDT-3606xsX4JJ@132.216.98.100
DTSTAMP:20250817T115832Z
DESCRIPTION:Join D2R and the Victor Phillip Dahdaleh Institute of Genomic M
 edicine for this hybrid seminar with Professor Richard Haynes from Oxford 
 University where he will present how Protas is changing the face of clinic
 al trials.\n\nRandomized trials remain the best methodology to assess the 
 efficacy and safety of treatments\, BUT they are facing a crisis. Rising r
 egulatory burden and costs mean that some effective treatments are either 
 not developed or are only developed for a narrow indication\, preventing t
 heir full benefits from being realized. Conversely\, less effective treatm
 ents may not be identified\, or worse\, their hazards may go unrecognized.
  Protas\, a not-for-profit organization\, intends to combine smart trial d
 esign and delivery\, effective use of data and technology and collaborativ
 e policy development to address this challenge and improve population heal
 th.\n\nAgenda\n\n\n	\n		\n			11:00am-11:05am\n			Welcome\n				By Mark Lathrop\, D2R Sci
 entific Director\n		\n		\n			11:05am-12:05pm\n			Protas\, Smarter Trials for Better 
 Health\n				By Richard Haynes\, Professor of Renal Medicine and Clinical Trial
 s\,\n				Oxford University\n		\n		\n			12:05pm-12:25pm\n			Q&A\n		\n		\n			12:25pm-12:30pm\n			Clo
 sing Remarks\n		\n	\n\n\nAbout the Speaker:\n\nRichard Haynes did his pre-cli
 nical medical studies in Cambridge before moving to Oxford for his clinica
 l studies and qualified in 2000. He came to Oxford University’s Clinical T
 rial Service Unit for a period of “out of programme” research in 2006 to w
 ork on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his tra
 ining in renal medicine in 2011 and was appointed as an honorary consultan
 t at the Oxford Kidney Unit. Alongside his clinical practice\, his researc
 h focusses on large-scale streamlined trials. He has delivered trials in c
 ardiovascular disease and was co-principal investigator of EMPA-KIDNEY whi
 ch demonstrated the efficacy and safety of empagliflozin in people with CK
 D. He also led his trials unit delivery of the RECOVERY trial which was th
 e largest trial of treatments for covid-19. He now combines his research a
 t CTSU with his role as Chief Scientist at Protas.\n\nReserve Your Spot No
 w! \n\nBe part of this transformative discussion on the future of medical 
 trials.\n\nRSVP by Tuesday September 17:\n\nRegister to join online\n\nWan
 t to attend in-person? Reserve your spot by emailing D2R.comms [at] mcgill
 .ca\n\nConfirmation emails will be provided to registered participants a f
 ew days before the event.\n
DTSTART:20240919T150000Z
DTEND:20240919T163000Z
LOCATION:Room 6001\, CA\, QC\, Montreal\, Genome Building
SUMMARY:Seminar | Protas - Smarter Trials for Better Health
URL:/dna-to-rna/channels/event/seminar-protas-smarter-
 trials-better-health-358742
END:VEVENT
END:VCALENDAR